Under construction – not a live service
Sign in
Not yet taking people in SwitzerlandNo phase

Blood test to track prostate cancer in men on active surveillance

Tests a blood test for spotting worsening prostate cancer in men under surveillance.

Key facts

Who runs it
Insel Gruppe AG, University Hospital Bern
Where
Bern, SwitzerlandSee the site
Trial code
Registry title
Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)
Status
Not yet recruiting
People taking part
350 people, planned
Started
1 Jul 2026
Expected to end
31 Aug 2028
Type of study
Observational
Treatments tested
  • Stockholm3
Record updated
22 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with low-risk prostate cancer who are on active surveillance, meaning they are watched closely instead of treated right away. It tests a blood test called Stockholm3.

Age
18 years or older
Sex
Men only
Disease stage
Low-risk prostate cancer (D'Amico risk classification), currently on active surveillance
Earlier treatment
Must not have had prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy). Must have first entered active surveillance after 1st January 2022.

Main reasons for not taking part

  • Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy)
  • Intermediate- or high-risk prostate cancer
  • Urinary catheter within the past 6-8 weeks
  • Contraindications to MRI or biopsy

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Adult Men ≥ 18 y. o
  • Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS)
  • First inclusion in Active Surveillance (AS) after 1st January 2022
  • Scheduled for follow-up with systematic and/or Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available

Who cannot take part

  • - Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy); Patient with intermediate- or high-risk prostate cancer; Urinary catheterization within the past 6-8 weeks; Contraindications to Magnetic Resonance Imaging (MRI) or biopsy

Where in Switzerland

  • Inselspital University Hospital of BernBern, SwitzerlandContact: Lafita Anselm, CRCNo longer taking part

About the trial

What the trial wants to find out

The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.

The group in the trial

  • Stockolm3 Blood test in prostate cancer patient under active surviellance

    Diagnostic procedure

    Treatment: Stockholm3

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multicenter Validation of the Stockholm3 Test on Men on Active Surveillance: the CHAS3-Trial
Plain-language title
Blood test to track prostate cancer in men on active surveillanceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 June 2026